440 related articles for article (PubMed ID: 8858891)
21. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes.
Kirchheiner J; Seeringer A
Biochim Biophys Acta; 2007 Mar; 1770(3):489-94. PubMed ID: 17113714
[TBL] [Abstract][Full Text] [Related]
22. Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS; Kim D
Arch Pharm Res; 2011 Nov; 34(11):1799-816. PubMed ID: 22139682
[TBL] [Abstract][Full Text] [Related]
23. Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms.
Spigset O; Granberg K; Hägg S; Norström A; Dahlqvist R
Eur J Clin Pharmacol; 1997; 52(2):129-33. PubMed ID: 9174682
[TBL] [Abstract][Full Text] [Related]
24. [Clinical significance of cytochrome P450 genetic polymorphism--part I. Enzymatic system of cytochrome P450 and cytochrome P450 1A2].
Duricová J; Grundmann M
Ceska Slov Farm; 2011 Jun; 60(3):110-5. PubMed ID: 21838140
[TBL] [Abstract][Full Text] [Related]
25. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
26. Identification of the human cytochromes P450 responsible for atomoxetine metabolism.
Ring BJ; Gillespie JS; Eckstein JA; Wrighton SA
Drug Metab Dispos; 2002 Mar; 30(3):319-23. PubMed ID: 11854152
[TBL] [Abstract][Full Text] [Related]
27. Bench to bedside: Pharmacogenomics, adverse drug interactions, and the cytochrome P450 system.
Sikka R; Magauran B; Ulrich A; Shannon M
Acad Emerg Med; 2005 Dec; 12(12):1227-35. PubMed ID: 16282513
[TBL] [Abstract][Full Text] [Related]
28. [Genetic polymorphism in human drug metabolism].
Yamazoe Y; Nagata K
Nihon Yakurigaku Zasshi; 1993 Feb; 101(2):69-77. PubMed ID: 8454228
[TBL] [Abstract][Full Text] [Related]
29. Polymorphic drug metabolizing CYP-enzymes--a pathogenic factor in oral lichen planus?
Kragelund C; Hansen C; Reibel J; Nauntofte B; Broesen K; Pedersen AM; Smidt D; Eiberg H; Torpet LA
J Oral Pathol Med; 2009 Jan; 38(1):63-71. PubMed ID: 19192051
[TBL] [Abstract][Full Text] [Related]
30. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine.
Skjelbo E; Brøsen K; Hallas J; Gram LF
Clin Pharmacol Ther; 1991 Jan; 49(1):18-23. PubMed ID: 1988236
[TBL] [Abstract][Full Text] [Related]
31. Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. III. Influence of CYP genetic polymorphism on population differentiation of drug metabolism phenotype.
Tomaszewski P; Kubiak-Tomaszewska G; Łukaszkiewicz J; Pachecka J
Acta Pol Pharm; 2008; 65(3):319-29. PubMed ID: 18646551
[TBL] [Abstract][Full Text] [Related]
32. Investigation of xenobiotic metabolism by CYP2D6 and CYP2C19: importance of enantioselective analytical methods.
Marzo A; Balant LP
J Chromatogr B Biomed Appl; 1996 Mar; 678(1):73-92. PubMed ID: 8861658
[TBL] [Abstract][Full Text] [Related]
33. Genes and the response to drugs.
Caraco Y
N Engl J Med; 2004 Dec; 351(27):2867-9. PubMed ID: 15625340
[No Abstract] [Full Text] [Related]
34. Identification of Cytochrome P450-Mediated Drug-Drug Interactions at Risk in Cases of Gene Polymorphisms by Using a Quantitative Prediction Model.
Fermier N; Bourguignon L; Goutelle S; Bleyzac N; Tod M
Clin Pharmacokinet; 2018 Dec; 57(12):1581-1591. PubMed ID: 29572664
[TBL] [Abstract][Full Text] [Related]
35. Polymorphic drug oxidation in humans.
Eichelbaum M
Fed Proc; 1984 May; 43(8):2298-302. PubMed ID: 6714436
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of the sparteine/debrisoquine oxidation polymorphism.
Brøsen K; Gram LF
Eur J Clin Pharmacol; 1989; 36(6):537-47. PubMed ID: 2570698
[TBL] [Abstract][Full Text] [Related]
37. Individuality in cytochrome P450 expression and its association with the nephrotoxic and carcinogenic effects of chemicals.
Wolf CR
IARC Sci Publ; 1991; (115):281-7. PubMed ID: 1820342
[TBL] [Abstract][Full Text] [Related]
38. Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition.
Niwa T; Murayama N; Yamazaki H
Curr Drug Metab; 2011 Jun; 12(5):412-35. PubMed ID: 21453270
[TBL] [Abstract][Full Text] [Related]
39. Influence of pharmacogenetics on drug disposition and response.
Eichelbaum M; Evert B
Clin Exp Pharmacol Physiol; 1996; 23(10-11):983-5. PubMed ID: 8911746
[TBL] [Abstract][Full Text] [Related]
40. Pharmacogenetics of drug oxidation via cytochrome P450 (CYP) in the populations of Denmark, Faroe Islands and Greenland.
Brosen K
Drug Metab Pers Ther; 2015 Sep; 30(3):147-63. PubMed ID: 25719307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
